SCHEMBL10043799

SCHEMBL10043799

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1-c1cc2cnc(CCc3ccc(C(F)(F)F)cc3)cc2n(C)c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.62
LCK P06239 3/20 0.50
KDR P35968 3/20 0.50
JAK3 P52333 2/20 0.50
MAPK14 Q16539 2/20 0.50
TEK Q02763 2/20 0.50
RAF1 P04049 13/20 0.49
BRAF P15056 13/20 0.49
DDR2 Q16832 1/20 0.49
ABL1 P00519 2/20 0.47
FES P07332 1/20 0.46
RET P07949 1/20 0.46
PDGFRB P09619 1/20 0.46
KIT P10721 1/20 0.46
FGFR1 P11362 1/20 0.46
SRC P12931 1/20 0.46
PDGFRA P16234 1/20 0.46
FLT1 P17948 1/20 0.46
FGFR3 P22607 1/20 0.46
EPHA3 P29320 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10072022 0.97 SYK (0.62) SYKLCKKDRJAK3MAPK14
SCHEMBL10043790 0.96 SYK (0.61) SYKLCKKDRJAK3MAPK14
SCHEMBL10044001 0.96 SYK (0.61) SYKLCKKDRJAK3MAPK14
SCHEMBL10043997 0.92 SYK (0.65) SYKLCKKDRJAK3MAPK14
SCHEMBL502335 0.92 SYK (0.65) SYKLCKKDRJAK3MAPK14
SCHEMBL10043793 0.91 SYK (0.65) SYKLCKKDRJAK3MAPK14
SCHEMBL10043995 0.91 SYK (0.64) SYKLCKKDRJAK3MAPK14
SCHEMBL10044009 0.91 SYK (0.59) SYKLCKKDRJAK3MAPK14
SCHEMBL10072197 0.90 SYK (0.67) SYKLCKKDRJAK3MAPK14
SCHEMBL10044004 0.90 SYK (0.61) SYKLCKKDRJAK3MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885LCK 4/4885KDR 108/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885LCK 4/4885KDR 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.